CSL (OTCMKTS:CSLLY) Shares Gap Down – Here’s Why
by Renee Jackson · The Cerbat GemCSL Limited Sponsored ADR (OTCMKTS:CSLLY – Get Free Report)’s share price gapped down before the market opened on Monday . The stock had previously closed at $24.67, but opened at $23.62. CSL shares last traded at $24.6715, with a volume of 2,855 shares.
Analyst Ratings Changes
A number of equities analysts have recently commented on the stock. Royal Bank Of Canada downgraded shares of CSL from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, February 11th. Zacks Research upgraded shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy”.
View Our Latest Stock Analysis on CSL
CSL Stock Down 0.5%
The company’s 50 day moving average is $33.62 and its 200-day moving average is $51.63.
CSL Company Profile
CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.
The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.